Alpha Thalassemia Market research report: by type (hb bart syndrome, hbh disease, silent carrier state, and trait.), by diagnosis (perinatal testing, prenatal testing, and pre-implantation), Treatment, End user -forecast till 2032

TABLE OF CONTENT

Chapter 1. Report Prologue

Chapter 2. Market Introduction

2.1 Definition

2.2 Scope of the Study

2.2.1 Research Objective

2.2.2 Assumptions

2.2.3 Limitations

Chapter 3. Research Methodology

3.1 Introduction

3.2 Primary Research

3.3 Secondary Research

3.4 Market Size Estimation

Chapter 4. Market Dynamics

4.1 Drivers

4.2 Restrains

4.3 Opportunities

4.4 Challenges

4.5 Macroeconomic Indicators

4.6 Technology Trends & Assessment

Chapter 5. Market Factor Analysis

5.1 Porter’s Five Forces Analysis

5.1.1 Bargaining Power of Suppliers

5.1.2 Bargaining Power of Buyers

5.1.3 Threat of New Entrants

5.1.4 Threat of Substitutes

5.1.5 Intensity of Rivalry

5.2 Value Chain Analysis

5.3 Investment Feasibility Analysis

5.4 Pricing Analysis

Chapter 6. Global Alpha Thalassemia Market, By Type

6.1 Introduction

6.2 Hb Bart syndrome

6.2.1 Market Estimates & Forecast, 2020 – 2023

6.3 HbH disease

6.3.1 Market Estimates & Forecast, 2020 – 2023

6.4 Silent carrier state

6.4.1 Market Estimates & Forecast, 2020 – 2023

6.5 Trait

6.5.1 Market Estimates & Forecast, 2020 – 2023

Chapter 7. Global Alpha Thalassemia Market, By Diagnosis

7.1 Introduction

7.2 Perinatal testing

7.2.1 Market Estimates & Forecast, 2020-2027

7.2.2 Complete blood count (CBC)

7.2.2.1 Market Estimates & Forecast, 2020-2027

7.2.3 DNA testing

7.2.3.1 Market Estimates & Forecast, 2020-2027

7.3 Prenatal testing

7.3.1 Market Estimates & Forecast, 2020-2027

7.3.2 Prenatal Genetic Testing

7.3.2.1 Market Estimates & Forecast, 2020-2027

7.3.3 Chorionic Villus sampling

7.3.3.1 Market Estimates & Forecast, 2020-2027

7.4 Pre-implantation

7.4.1 Market Estimates & Forecast, 2020-2027

Chapter 8. Global Alpha Thalassemia Market, By Treatment

8.1 Introduction

8.2 Blood transfusions

8.2.1 Market Estimates & Forecast, 2020-2027

8.3 Iron chelation

8.3.1 Market Estimates & Forecast, 2020-2027

8.4 Bone marrow, or stem cell transplant

8.4.1 Market Estimates & Forecast, 2020-2027

8.5 Surgery

8.5.1 Market Estimates & Forecast, 2020-2027

8.6 Gene therapy

8.6.1 Market Estimates & Forecast, 2020-2027

Chapter 9. Global Alpha Thalassemia Market, By End User

9.1 Introduction

9.2 Hospitals

9.2.1 Market Estimates & Forecast, 2020-2027

9.3 Biotechnological laboratories

9.3.1 Market Estimates & Forecast, 2020-2027

9.4 Diagnostic laboratories

9.4.1 Market Estimates & Forecast, 2020-2027

9.5 Educational research institutes

9.5.1 Market Estimates & Forecast, 2020-2027

9.6 Pharmaceutical industries

9.6.1 Market Estimates & Forecast, 2020-2027

9.7 Others

Chapter. 10 Global Alpha Thalassemia Market, By Region

10.1 Introduction

10.2 Americas

10.2.1 North America

10.2.1.1 U.S.

10.2.1.2 Canada

10.2.2 South America

10.3 Europe

10.3.1 Western Europe

10.3.1.1 Germany

10.3.1.2 France

10.3.1.3 Italy

10.3.1.4 Spain

10.3.1.5 U.K

10.3.1.6 Rest of Western Europe

10.3.2 Eastern Europe

10.4 Asia Pacific

10.4.1 Japan

10.4.2 China

10.4.3 India

10.4.4 Australia

10.4.5 Republic Of Korea

10.4.6 Rest of Asia Pacific

10.5 The Middle East & Africa

10.5.1 United Arab Emirates

10.5.2 Saudi Arabia

10.5.3 Rest of the Middle East & Africa

Chapter 11 Company Landscape

11.1 Introduction

11.2 Market Share Analysis

11.3 Key Development & Strategies

11.3.1 Key Developments

Chapter 12 Company Profiles

12.1 GlaxoSmithKline Plc

12.1.1 Company Overview

12.1.2 Treatment Overview

12.1.3 Financials

12.1.4 SWOT Analysis

12.2 Celgene Corporation

12.2.1 Company Overview

12.2.2 Treatment Overview

12.2.3 Financial Overview

12.2.4 Key Developments

12.2.5 SWOT Analysis

12.3 Bellicum Pharmaceuticals

12.3.1 Company Overview

12.3.2 Treatment Overview

12.3.3 Financial Overview

12.3.4 Key Development

12.3.5 SWOT Analysis

12.4 Lonza group

12.4.1 Company Overview

12.4.2 Treatment/Business Segment Overview

12.4.3 Financial Overview

12.4.4 Key Development

12.4.5 SWOT Analysis

12.5 Acceleron Pharma

12.5.1 Company Overview

12.5.2 Treatment Overview

12.5.3 Financial Overview

12.5.4 Key Developments

12.6 BlueBird Bio

12.6.1 Company Overview

12.6.2 Treatment Overview

12.6.3 Financial Overview

12.6.4 Key Developments

12.7 Sangamo Biosciences

12.7.1 Overview

12.7.2 Treatment Overview

12.7.3 Financials

12.7.4 Key Developments

12.7.5 SWOT Analysis

12.8 Johnson & Johnson

12.8.1 Company Overview

12.8.2 Treatment/Business Segment Overview

12.8.3 Financial Overview

12.8.4 Key Development

12.8.5 SWOT Analysis

12.9 Merck & Co Inc.

12.9.1 Company Overview

12.9.2 Treatment Overview

12.9.3 Financial Overview

12.9.4 Key Developments

12.10 Others

Chapter 13 MRFR Conclusion

13.1 Key Findings

13.1.1 From CEO’s View Point

13.1.2 Unmet Needs of the Market

13.2 Key Companies to Watch

13.3 Prediction of Pharmaceutical Industry

Chapter 14 Appendix

LIST OF TABLES

Table 1 Alpha Thalassemia Industry Synopsis, 2020-2027

Table 2 Alpha Thalassemia Market Estimates and Forecast, 2020-2027, (USD Million)

Table 3 Alpha Thalassemia Market by Region, 2020-2027, (USD Million)

Table 4 Alpha Thalassemia Market by Type, 2020-2027, (USD Million)

Table 5 Alpha Thalassemia Market by Diagnosis, 2020-2027, (USD Million)

Table 6 Alpha Thalassemia Market by Treatment, 2020-2027, (USD Million)

Table 7 Alpha Thalassemia Market by End Users, 2020-2027, (USD Million)

Table 8 North America Alpha Thalassemia Market by Type, 2020-2027, (USD Million)

Table 9 North America Alpha Thalassemia Market by Diagnosis, 2020-2027, (USD Million)

Table 10 North America Alpha Thalassemia Market by Treatment, 2020-2027, (USD Million)

Table 11 North America Alpha Thalassemia Market by End User, 2020-2027, (USD Million)

Table 12 US Alpha Thalassemia Market By Type, 2020-2027, (USD Million)

Table 13 US Alpha Thalassemia Market By Diagnosis, 2020-2027, (USD Million)

Table 14 US Alpha Thalassemia Market By Treatment, 2020-2027, (USD Million)

Table 15 US Alpha Thalassemia Market By End User, 2020-2027, (USD Million)

Table 16 Canada Alpha Thalassemia Market by Type, 2020-2027, (USD Million)

Table 17 Canada Alpha Thalassemia Market by Diagnosis, 2020-2027, (USD Million)

Table 18 Canada Alpha Thalassemia Market by Treatment, 2020-2027, (USD Million)

Table 19 Canada Alpha Thalassemia Market by End User, 2020-2027, (USD Million)

Table 20 South America Alpha Thalassemia Market by Type, 2020-2027, (USD Million)

Table 21 South America Alpha Thalassemia Market by Diagnosis, 2020-2027, (USD Million)

Table 22 South America Alpha Thalassemia Market by Treatment, 2020-2027, (USD Million)

Table 23 South America Alpha Thalassemia Market by End User, 2020-2027, (USD Million)

Table 24 Europe Alpha Thalassemia Market by Type, 2020-2027, (USD Million)

Table 25 Europe Alpha Thalassemia Market by Diagnosis, 2020-2027, (USD Million)

Table 26 Europe Alpha Thalassemia Market by Treatment, 2020-2027, (USD Million)

Table 27 Europe Alpha Thalassemia Market by End User, 2020-2027, (USD Million)

Table 28 Western Europe Alpha Thalassemia Market by Type, 2020-2027, (USD Million)

Table 29 Western Europe Alpha Thalassemia Market by Diagnosis, 2020-2027, (USD Million)

Table 30 Western Europe Alpha Thalassemia Market by Treatment, 2020-2027, (USD Million)

Table 31 Western Europe Alpha Thalassemia Market by End User, 2020-2027, (USD Million)

Table 32 Eastern Europe Alpha Thalassemia Market by Type, 2020-2027, (USD Million)

Table 33 Eastern Europe Alpha Thalassemia Market by Diagnosis, 2020-2027, (USD Million)

Table 34 Eastern Europe Alpha Thalassemia Market by Treatment, 2020-2027, (USD Million)

Table 35 Eastern Europe Alpha Thalassemia Market by End User, 2020-2027, (USD Million)

Table 36 Asia Pacific Alpha Thalassemia Market by Type, 2020-2027, (USD Million)

Table 37 Asia Pacific Alpha Thalassemia Market by Diagnosis, 2020-2027, (USD Million)

Table 38 Asia Pacific Alpha Thalassemia Market by Treatment, 2020-2027, (USD Million)

Table 39 Asia Pacific Alpha Thalassemia Market by End User, 2020-2027, (USD Million)

Table 40 The Middle East & Africa Alpha Thalassemia Market by Type, 2020-2027, (USD Million)

Table 41 The Middle East & Africa Alpha Thalassemia Market by Diagnosis, 2020-2027, (USD Million)

Table 42 The Middle East & Africa Alpha Thalassemia Market by Treatment, 2020-2027, (USD Million)

Table 43 The Middle East & Africa Alpha Thalassemia Market by End User, 2020-2027, (USD Million)

LIST OF FIGURES

Figure 1 Research Process

Figure 2 Segmentation for Alpha Thalassemia Market

Figure 3 Segmentation Market Dynamics for Alpha Thalassemia Market

Figure 4 Global Alpha Thalassemia Market Share, By Type 2020

Figure 5 Global Alpha Thalassemia Market Share, By Diagnosis 2020

Figure 6 Global Alpha Thalassemia Market Share, By Treatment, 2020

Figure 9 Global Alpha Thalassemia Market Share, By End Users, 2020

Figure 10 Global Alpha Thalassemia Market Share, By Region, 2020

Figure 11 North America Alpha Thalassemia Market Share, By Country, 2020

Figure 12 Europe Alpha Thalassemia Market Share, By Country, 2020

Figure 13 Asia Pacific Alpha Thalassemia Market Share, By Country, 2020

Figure 14 the Middle East & Africa Alpha Thalassemia Market Share, By Country, 2020

Figure 15 Global Alpha Thalassemia Market: Company Share Analysis, 2020 (%)

Figure 16 GlaxoSmithKline Plc: Key Financials

Figure 17 GlaxoSmithKline Plc: Segmental Revenue

Figure 18 GlaxoSmithKline Plc: Geographical Revenue

Figure 19 Celgene Corporation: Key Financials

Figure 20 Celgene Corporation: Segmental Revenue

Figure 21 Celgene Corporation: Geographical Revenue

Figure 22 Bellicum Pharmaceuticals: Key Financials

Figure 23 Bellicum Pharmaceuticals: Segmental Revenue

Figure 24 Bellicum Pharmaceuticals: Geographical Revenue

Figure 25 Lonza group: Key Financials

Figure 26 Lonza group: Segmental Revenue

Figure 27 Lonza group: Geographical Revenue

Figure 28 Acceleron Pharma: Key Financials

Figure 29 Acceleron Pharma: Segmental Revenue

Figure 30 Acceleron Pharma: Geographical Revenue

Figure 32 BlueBird Bio: Key Financials

Figure 33 BlueBird Bio: Segmental Revenue

Figure 34 BlueBird Bio: Geographical Revenue

Figure 35 Sangamo Biosciences: Key Financials

Figure 36 Sangamo Biosciences: Segmental Revenue

Figure 37 Sangamo Biosciences: Geographical Revenue

Figure 38 Johnson & Johnson: Key Financials

Figure 39 Johnson & Johnson: Segmental Revenue

Figure 40 Johnson & Johnson: Geographical Revenue

Figure 41 Merck & Co Inc.: Key Financials

Figure 42 Merck & Co Inc.: Segmental Revenue

Figure 43 Merck & Co Inc.: Geographical Revenue